Phase II trial of XXXX (Taxotere) in metastatic @entity14 .

@entity1 @entity137 @entity19 @entity4 @entity1149 @entity3028 @entity1398 @entity56 @entity14 @entity694 @entity1205
BACKGROUND: @entity1205 (Taxotere) is prepared from a noncytotoxic precursor extracted from the needles of the Taxus baccata. Preclinical investigations have demonstrated that @entity1205 is very active in @entity694 @entity19 models. Phase I studies revealed @entity3028 to be the dose-limiting @entity137 . Initial clinical trials also demonstrated @entity1205 's activity in ovarian, breast, and @entity1149 . Because of this encouraging preclinical and clinical activity, we initiated a phase II study of @entity1205 in @entity1 with metastatic @entity14 . @entity1 AND METHODS: @entity1205 , 100 mg/m2, was administered as a 1-hour intravenous infusion every 21 days. Nineteen @entity1 were entered on the trial. All @entity1 had measurable disease and had not received prior chemotherapy for metastatic disease. RESULTS: No complete or partial responses were observed. @entity3028 was the dose-limiting toxic effect. Seventeen @entity1 had grade 4 @entity3028 ; 8 of these patients received antibiotics for @entity1398 fevers. Twelve @entity1 experienced @entity56 , and 15 @entity1 experienced cutaneous toxic reactions. One @entity1 demonstrated evidence of fluid retention. CONCLUSIONS: Administered at the stated dose and schedule, @entity1205 has little activity against metastatic @entity14 . The @entity137 profile, consisting of @entity3028 , @entity56 , cutaneous reactions, and @entity4 , has been previously described in @entity1 receiving @entity1205 .
